$CAMX (-3,95%) I will remain invested here as well.
Oczyesa is now available for patients with acromegaly in Germany.
First once-monthly, subcutaneous octreotide treatment
Developed for self-administration and effective disease control
Lund, Sweden - November 3, 2025 - Camurus (NASDAQ STO: CAMX) today announced the launch of Oczyesa in Germany, the first country in the EU to do so. Oczyesa® , an octreotide depot preparation for subcutaneous administration, is approved for maintenance treatment in adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.<sup> 1 </sup>
"We are pleased to announce that Oczyesa is now available for patients with acromegaly following marketing authorization by the European Commission," said Fredrik Tiberg, President and CEO and CSO of Camurus. "The drug enables sustained disease control and can be self-administered using an auto-injector. This improves the patient's quality of life and satisfaction with the treatment. Oczyesa will initially be launched in Germany; the market launch in other EU countries is planned."
An estimated 70,000 people in the EU live with acromegaly.
"There remains a significant unmet medical need for patients with acromegaly. They are often faced with a high treatment burden and a reduced quality of life," says Prof. Günter Stalla, Head of Medicover Neuroendocrinology in Munich. "Oczyesa offers a welcome new alternative that combines effective disease control with easy self-administration. This empowers patients and helps to optimize health resources."
Full article at the link ⬇️
